virtual CROI 2021 Schedule at a Glance Version 3 (Short)
LIVE PROGRAM
TIME SATURDAY, MARCH 6, 2021 SUNDAY, MARCH 7, 2021
10:00 AM W-1 PROGRAM COMMITTEE WORKSHOP FOR NEW INVESTIGATORS AND TRAINEES OPENING SESSION (10:00 – 12:05) EST (10:00 – 14:00) CHAIRS WELCOME TO virtual CROI 2021 START Conveners: Serena S. Spudich and Nicolas Chomont Chairs: Sharon L. Hillier, James A. Hoxie, and Elaine J. Abrams ADVANCES IN MOLECULAR VIROLOGY OF HIV AND SARS-CoV-2 MARTIN DELANEY PRESENTATION
LIVE PROGRAM LIVE Frank Kirchhoff INTRODUCTION ADVANCES IN HIV AND SARS-CoV-2 IMMUNOLOGY James Pickett Galit Alter VACCINE NATIONALISM IS KILLING US: HOW INEQUITIES IN RESEARCH AND ACCESS TO SARS-CoV-2 VACCINES WILL PERPETUATE THE PANDEMIC ADVANCES IN COVID-19 TREATMENT STRATEGIES AND CONTROLLING THE EPIDEMIC Gregg S. Gonsalves and Fatima Hassan Jürgen Rockstroh BERNARD FIELDS LECTURE ADVANCES IN BIOMEDICAL PREVENTION OF HIV INTRODUCTION Jean-Michel Molina James A. Hoxie and Galit Alter ADVANCES IN HIV CURE NEUTRALIZING ANTIBODIES AGAINST CORONAVIRUSES Katherine J. Bar Pamela J. Bjorkman N'GALY-MANN LECTURE INTRODUCTION Elaine J. Abrams and Tedros Adhanom Ghebreyesus LESSONS FROM THE CONCURRENT HIV/AIDS AND COVID-19 PANDEMICS: A TWO-WAY STREET Anthony S. Fauci
12:20 PM CONCURRENT WORKSHOPS (12:20 – 2:20) EST W-2 FRONTIERS IN LABORATORY TECHNOLOGIES
Conveners: Galit Alter and Frank Kirchhoff STRUCTURES OF SARS-CoV-2 ANTIBODIES INDUCED BY INFECTION AND mRNA VACCINES Christopher O. Barnes
EMERGING CONCEPTS IN HIV-1 RESTRICTION
Edward Campbell SARS-CoV-2 SPECIFIC AND CROSS-REACTIVE T CELL RESPONSES Daniela Weiskopf
ARTIFICIAL INTELLIGENCE-INSPIRED ANTIBODY ENGINEERING Sai Reddy W-3 CLINICAL TRIAL DESIGN AND ANALYSIS
Conveners: Susan P. Buchbinder and Richard E. Chaisson MAKING SENSE OF STUDY DESIGN DIFFERENCES BETWEEN COVID-19 PLATFORM TRIALS Lori Dodd DESIGN OF CURRENT AND FUTURE COVID-19 VACCINE EFFICACY TRIALS Holly Janes W-4 CASE TRACING AND CASE MANAGEMENT: COVID-19 WORKSHOP Conveners: Robert T. Schooley and David L. Thomas RAPID GENOMIC SEQUENCING FOR MANAGEMENT OF COVID-19 Kwok-Yung Yuen COVID-19: A HOSPITALISED UNWELL PATIENT WITH PNEUMONITIS Sanjay Bhagani CRITICAL CARE OF COVID-19 Janhavi Athale
LIVE PROGRAM Last Updated on March 4, 2021 LIVE PROGRAM TIME MONDAY, MARCH 8, 2021 TUESDAY, MARCH 9, 2021 WEDNESDAY, MARCH 10, 2021
10:00 PLENARY SESSION (10:00 – 11:00) PLENARY SESSION (10:00 – 11:00) PLENARY SESSION (10:00 – 11:00) AM EST Session Hosts: Wesley Sundquist and Carlos del Rio Session Hosts: Peter W. Hunt and Sharon L. Hillier Session Hosts: Nicolas Chomont and Elaine J. Abrams START WELCOME AND DAILY ROADMAP WELCOME AND DAILY ROADMAP WELCOME AND DAILY ROADMAP Sharon L. Hillier Elaine J. Abrams James A. Hoxie P-1 IMAGING VIRAL LIFE CYCLES P-3 HIV-1 bNAbs: LOOKING AHEAD P-5 ELITE CONTROLLERS: A MODEL FOR A FUNCTIONAL CURE OF HIV-1 INFECTION Hans-Georg Kräusslich Marina Caskey Xu Yu P-2 DISPARITIES IN HEALTH: FROM HIV TO COVID-19 AND BEYOND P-4 SUSTAINED DELIVERY AND LONG-ACTING AGENTS FOR PREVENTION OF HIV P-6 HIV TREATMENT IN PREGNANCY: BEYOND PREVENTION OF VERTICAL TRANSMISSION James E. Hildreth Linda-Gail Beker Shahin Lockman
LIVE PROGRAM LIVE
11:15 AM CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) CONCURRENT ORAL ABSTRACT SESSIONS (11:15 – 1:15) EST O-1 HIV/SIV HOST AND CELLULAR INTERCTIONS: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS O-5 SARS-CoV-2 VS HOST: VIROLOGY, IMMUNOLOGY, AND PATHOGENESIS O-10 HIV RESERVOIRS Oral Abstract Moderators: John M. Coffin and Richard A. Koup Oral Abstract Moderators: Wesley I. Sundquist and Guido Silvestri Oral Abstract Moderators: Douglas D. Richman and Katharine J. Bar DECIPHERING THE HOST NUCLEUS SUBVERSION BY HIV-1 TO REPLICATE IFITM PROTEINS PROMOTE SARS-CoV-2 INFECTION IN HUMAN LUNG CELLS INFECTED CELLS ARE CLONOTYPICALLY DIVERSE IN BLOOD & LYMPH NODES SINCE FIEBIG STAGE I Francesca Di Nunzio Caterina Prelli Bozzo Pierre Gantner HIV-1 CAPSID RETAINS ITS INTEGRITY UNTIL MINUTES BEFORE UNCOATING IN THE NUCLEUS SARBECOVIRUS ORF6 PROTEINS ANTAGONIZE INTERFERON SIGNALING EVOLUTIONARY DYNAMICS OF HIV RESERVOIR CELLS VIA A NOVEL SINGLE-CELL MULTIOMICS ASSAY Chenglei Li Izumi Kimura Kevin B. Einkauf TRAFFICKING OF HIV-1 ENVELOPE TO THE EHD1/MICAL-L1 TUBULAR-SORTING ENDOSOME SEVERE COVID-19 IS FUELED BY DISRUPTED GUT BARRIER INTEGRITY NONINVASIVE PLASMA GLYCOMIC AND METABOLIC BIOMARKERS OF POSTTREATMENT HIV CONTROL Paul Spearman Leila B. Giron Leila B. Giron A COMPREHENSIVE CRISPR SCREEN FOR HIV DEPENDENCY FACTORS SARS-CoV-2 PERSISTS IN INTESTINAL ENTEROCYTES UP TO 7 MONTHS AFTER SYMPTOM RESOLUTION PD-1 BLOCKADE ENHANCES THERAPEUTIC BENEFITS OF VACCINE IN A CHRONIC SIV/MACAQUE MODEL Vanessa R. Montoya Minami Tokuyama Sheikh A. Rahman EARLY bNAb THERAPY IN SHIVAD8-EO–INFECTED RHESUS MACAQUES COVID-19 OUTCOME: INSIGHTS FROM QUANTIFICATION OF VIREMIA AND NEUTRALIZING ANTIBODY TYPE I INTERFERON-ASSOCIATED GENE EXPRESSION PREDICTS TIME TO VIRAL REBOUND ON TI Joana Dias Penny Zacharopoulou IMMUNE CORRELATES OF POSTTREATMENT CONTROL IN SHIV-INFECTED INFANT MACAQUES Jana L. Jacobs Veronica Obregon-Perko CHARACTERIZATION AND EPITOPE MAPPING OF SARS-CoV-2–SPECIFIC T CELLS HIV-1 PROVIRUS CANNOT BE REACTIVATED IN PATIENTS ON TREATMENT WITH ART AND DASATINIB SIV∆GY INFECTION INDUCES ELITE CONTROL AND RESISTANCE TO SHIV HETEROLOGOUS CHALLENGE Kristin L. Boswell Mayte Coiras Susan Pereira Ribeiro BARICITINIB LOWERS INFLAMMATION AND PATHOLOGY IN SARS-CoV-2–INFECTED RHESUS MACAQUES DURABLE HIV-1 ANTIBODY PRODUCTION IN HUMANS AFTER AAV8-MEDIATED GENE TRANSFER TRAPPING THE HIV-1 V3 LOOP IN A HELICAL CONFORMATION ENABLES BROAD NEUTRALIZATION Timothy Hoang Joseph P. Casazza Matthias Glögl ONE DOSE OF COVID-19 mRNA VACCINE IN SARS-CoV-2–EXPERIENCED PEOPLE MAY BE SUFFICIENT A PLACEBO-CONTROLLED ATI TRIAL OF HTI VACCINES IN EARLY TREATED HIV INFECTION AN Env-gag mRNA VACCINE PROTECTS MACAQUES FROM HETEROLOGOUS TIER-2 SHIV INFECTION Mark Mulligan Beatriz Mothe Peng Zhang SARS-CoV-2 RECRUITS A HAEM METABOLITE TO EVADE ANTIBODY IMMUNITY O-11 BRAIN CONNECTIONS, MALIGNANCIES, AND TUMOR VIRUSES O-2 HIV TREATMENT AND PREVENTION: NEW OPPORTUNITIES TO OPTIMIZE DRUG DOSING, ADHERENCE, AND Annachiara Rosa Oral Abstract Moderators: Dennis L. Kolson and Ronald T. Mitsuyasu ANTIRETROVIRAL THERAPY O-6 NEW WEAPONS AGAINST SARS-CoV-2 AND HIV NEURON DAMAGE AND RESERVOIR ARE SECONDARY TO HIV TRANSCRIPTS DESPITE SUPPRESSIVE ART Oral Abstract Moderators: Angela Kashuba and Courtney V. Fletcher Oral Abstract Moderators: Kazuo Suzuki ISLATRAVIR PK THRESHOLD & DOSE SELECTION FOR MONTHLY ORAL HIV-1 PrEP Joseph J. Eron and Douglas D. Richman 3T BRAIN MRS REVEALS DISTINCT METABOLITE PATTERNS OF ART INITIATION DURING ACUTE HIV Munjal Patel BAMLANIVIMAB PREVENTS COVID-19 MORBIDITY AND MORTALITY IN NURSING-HOME SETTING Napapon Sailasuta NEXT-GENERATION ISLATRAVIR IMPLANTS PROJECTED TO PROVIDE YEARLY HIV PROPHYLAXIS Myron S. Cohen EFFECTS OF HIV AND AGING ON FUNCTIONAL CONNECTIVITY AND ANATOMY Randolph P. Matthews BAMLANIVIMAB+ETESEVIMAB FOR TREATMENT OF COVID-19 IN HIGH-RISK AMBULATORY PATIENTS Patrick H. Luckett CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS Michael Dougan DIVERGENT AND SELF-REACTIVE IMMUNE RESPONSES IN THE CNS OF COVID-19 PATIENTS Justin Lutz CASIRIVIMAB WITH IMDEVIMAB ANTIBODY COCKTAIL FOR COVID-19 PREVENTION: INTERIM RESULTS Shelli F. Farhadian PK AND SAFETY OF HIGH-DOSE RIFAMPICIN IN TB/HIV COINFECTED PATIENTS ON EFV OR DTG Meagan P. O'Brien CHROMOSOMAL COPY NUMBER ALTERATIONS IN ANAL PRECANCERS FROM PEOPLE WITH HIV Christine Sekaggya-Wiltshire POTENT NEUTRALIZING ANTIBODIES FOR SEVERE COVID-19: A RANDOMIZED CLINICAL TRIAL Tinaye Mutetwa PK OF DOSE-ADJUSTED EMERGENCY CONTRACEPTION WITH EFV-BASED ART IN ACTG 5375 Carlijn Jordans POMALIDOMIDE AND LIPOSOMAL DOXORUBICIN FOR KAPOSI SARCOMA +/– OTHER KSHV DISEASES Kimberly K. Scarsi ESTIMATING WITHIN-HOST R0 FOR SARS-CoV-2 AND IMPLICATIONS FOR ANTIVIRAL THERAPY Ramya Ramaswami EMTRICITABINE TRIPHOSPHATE IN DRIED BLOOD SPOTS PREDICTS FUTURE VIREMIA IN PWH Ruian Ke VAGINAL pH PREDICTS CERVICAL INTRAEPITHELIAL NEOPLASIA-2 REGRESSION IN HIV+ WOMEN Jose R. Castillo-Mancilla PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254 Katherine G. Michel TENOFOVIR DIPHOSPHATE TO PREDICT FUTURE VIRAEMIA IN POSTPARTUM WOMEN LIVING WITH HIV Christoph Spinner WILMS' TUMOR 1 IS OVEREXPRESSED IN KAPOSI SARCOMA AND IS REGULATED BY VFLIP/K13 Jasantha Odayar POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH Ayana Morales NUCLEOSIDES AND DARUNAVIR/DOLUTEGRAVIR IN AFRICA (NADIA) TRIAL: 48WKS PRIMARY OUTCOME Sorana Segal-Maurer INFLAMMASOME ACTIVATION IN PATIENTS WITH KSHV-ASSOCIATED DISORDERS Nicholas Paton ACTIVITY AND RESISTANCE HARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR Ramya Ramaswami RANDOMIZED TRIAL OF RESISTANCE TESTING FOR VIROLOGIC FAILURE IN SUB-SAHARAN AFRICA Laurie VanderVeen O-12 MATERNAL AND CHILD HIV AND SARS-CoV-2 Mark Siedner RESISTANCE PROFILE OF MK-8507, A NOVEL NNRTI SUITABLE FOR WEEKLY ORAL HIV TREATMENT Oral Abstract Moderators: Landon Myer and Hermione Lyall O-3 COMPLICATIONS OF HIV AND COVID-19 Tracy L. Diamond COVID-19 INFECTION IN HIGH-RISK SOUTH AFRICAN PREGNANCIES WITH AND WITHOUT HIV Oral Abstract Moderators: Judith S. Currier and Peter W. Hunt O-7 TUBERCULOSIS AND HEPATITIS Liesl De Waard SHORT-COURSE ALENDRONATE FOR THE PREVENTION OF ART-ASSOCIATED BONE LOSS Oral Abstract Moderators: CHARACTERISATION OF SARS-CoV-2–INFECTED CHILDREN DEVELOPING NEUTRALISING ANTIBODIES Tara McGinty Constance A. Benson and Robert T. Schooley Alessandra Ruggiero PREVENTION OF CARDIOVASCULAR DISEASE IN PERSONS WITH AND WITHOUT HIV RIFAPENTINE +/– MOXIFLOXACIN FOR PULMONARY TUBERCULOSIS IN PEOPLE WITH HIV PEDIATRIC AND ADOLESCENT HIV TESTING AND DIAGNOSIS IN THE CONTEXT OF COVID-19 Michael J. Silverberg April Pettit Jessica M. Gross SEX MODIFIES THE ASSOCIATION BETWEEN INFLAMMATION AND VASCULAR EVENTS IN TREATED HIV HIGH-DOSE RIFAMPICIN FOR HIV-ASSOCIATED TB MENINGITIS: A PHASE II RANDOMISED TRIAL DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI-BASED ART IN CHILDREN AND ADOLESCENTS Samuel R. Schnittman Fiona Cresswell Anna Turkova IDENTIFICATION OF UNIQUE PROTEINS PREDICTIVE OF MORTALITY AND MECHANISMS IN HIV BICTEGRAVIR CONCENTRATIONS AND VIROLOGIC RESPONSES IN PLWH RECEIVING 1HP FOR LTBI DolPHIN2 FINAL RESULTS DOLUTEGRAVIR VS EFAVIRENZ IN LATE PREGNANCY TO 72W POSTPARTUM Priscilla Hsue Hsin-Yun Sun Thokozile R. Malaba BIOLOGICAL PROFILES PREDICT CORONARY ARTERY DISEASE IN PWH AND RISK-MATCHED CONTROLS A CLUSTER RANDOMIZED TRIAL OF CONTACT TRACING IN HOUSEHOLDS OF INDEX PATIENTS WITH TB ANTEPARTUM WEIGHT GAIN AND ADVERSE PREGNANCY OUTCOMES IN IMPAACT 2010 Padraig McGettrick Neil A. Martinson Risa M. Hoffman 12-YEAR COGNITIVE DECLINE IS ASSOCIATED WITH LUNG DISEASE, DIABETES, AND DEPRESSION A CLUSTER RANDOMIZED TRIAL OF TARGETED UNIVERSAL TESTING FOR TB IN CLINICS SAFETY/EFFICACY OF DTG VS EFV, TDF VS TAF IN PREGNANCY/POSTPARTUM: IMPAACT 2010 TRIAL Scott Letendre Limakatso Lebina Lameck Chinula MULTIMORBIDITY IN PEOPLE WITH HIV USING ART IN THE US: PROJECTIONS TO 2030 A SIMPLE AND SAFE APPROACH TO HCV TREATMENT: FINDINGS FROM THE A5360 (MINMON) TRIAL ADVERSE PREGNANCY OUTCOMES AMONG HIV-INFECTED WOMEN EXPOSED TO ISONIAZID IN BRIEF-TB Parastu Kasaie Sunil S. Solomon Amita Gupta COVID-19 HOSPITALIZATION AMONG PEOPLE WITH HIV OR SOLID ORGAN TRANSPLANT IN THE US HEPATOCELLULAR CARCINOMA AND HBV VIREMIA IN HIV/HBV-COINFECTED PERSONS IN NA-ACCORD O-13 INNOVATIONS AND CHALLENGES IN TESTING, PREVENTION, AND CARE Jing Sun H. Nina Kim Oral Abstract Moderators: Jonathan Mermin and Wafaa M. El-Sadr O-4 IDENTIFYING DISPARITIES AND OPPORTUNITIES IN HIV UPRISING CIRCULATION OF HBV-COMPLEX PROFILES WITH HBsAg VACCINE-ESCAPE MUTATIONS PrEP USE DURING ACUTE HIV INFECTION IN A COMMUNITY SETTING COMPROMISES HIV DIAGNOSIS Oral Abstract Moderators: Richard E. Chaisson and Adaora Adimora Lorenzo Piermatteo Donn J. Colby DISPARITIES IN TIMELY RECEIPT OF ART PRESCRIPTION IN HIV CARE IN THE US, 2012-2018 O-8 COVID EPIDEMIOLOGY AND ITS IMPACT ON HIV CARE AND PREVENTION A CLUSTER-RANDOMIZED TRIAL OF TRADITIONAL HEALERS DELIVERING HIV TESTING IN UGANDA Jun Li Oral Abstract Moderators: Susan P. Buchbinder and James McIntyre Radhika Sundararajan GEOGRAPHIC DIFFERENCES IN TIME TO VIRAL SUPPRESSION IN THE DEEP SOUTH, 2012-2019 PHYLOGENETIC ANALYSIS OF THE TIMING OF SARS-CoV-2 INTRODUCTIONS INTO WASHINGTON STATE HIV SELF-TESTING TO OPTIMIZE FACILITY TESTING: A CLUSTER-RANDOMIZED TRIAL IN MALAWI Aadia Rana Diana M. Tordoff Kathryn Dovel DECREASED HIV DIAGNOSES AMONG MSM OF COLOR IN THRIVE-FUNDED JURISDICTIONS, 2014-2018 FROM TESTING TO MORTALITY: COVID-19 AND THE INVERSE CARE LAW IN SWITZERLAND COMMUNITY MULTIMONTH ART PROVISION: POOLED ANALYSIS OF 2 CLUSTER-RANDOMIZED TRIALS Kashif Iqbal Julien Riou John Lopes GENDER-AFFIRMING SURGERY ASSOCIATED WITH HIGH VIRAL SUPPRESSION AMONG TRANSGENDER PWH SEX/GENDER DIFFERENCES IN TESTING, PRESENTATION, AND OUTCOMES OF SARS-CoV-2 INFECTION POINT-OF-CARE URINE TENOFOVIR VERSUS SELF-REPORTED ART ADHERENCE IN ROUTINE HIV CARE Cristina Rodriguez-Hart Eileen P. Scully Yolanda Gomba HIV TRENDS AMONG THE AMERICAN INDIAN/ALASKA NATIVES, 2014-2018 RACIAL DISPARITIES IN COVID-19 POSITIVITY AMONG PEOPLE LIVING WITH HIV IN THE US RAPID VS SAME-DAY TREATMENT INITIATION FOR PATIENTS WITH TB SYMPTOMS AT HIV DIAGNOSIS Sophie Sembajwe Jessica Y. Islam Nancy Dorvil LOWER UPTAKE OF DOLUTEGRAVIR AMONG WOMEN OF REPRODUCTIVE POTENTIAL VS MEN—KENYA HIV AND COVID-19 INPATIENT OUTCOMES: A MATCHED RETROSPECTIVE MULTICENTRE ANALYSIS COMMUNITY DISTRIBUTION OF ART DURING CIVIL UNREST AND COVID-19 IN HAITI Matthew L. Romo Ming J. Lee Patrice Joseph RCT OF AN ONLINE MENTAL HEALTH INTERVENTION AMONG OLDER PLWH DURING COVID-19 PANDEMIC CHANGES IN HIV TESTING SERVICES AFTER COVID-19 IN 11 SUB-SAHARAN AFRICAN COUNTRIES RESILIENCE OF HIV ACTIVITIES DURING COVID-19 PANDEMIC AT HEALTH FACILITIES IN AFRICA Peter Mazonson Bakary Drammeh Tiffany G. Harris FEE FOR HOME DELIVERY AND MONITORING OF ART RAISES VIRAL SUPPRESSION IN SOUTH AFRICA DRAMATIC DECLINE IN PUBLIC SECTOR HIV/STI TESTING DURING SARS-CoV-2 PANDEMIC, OREGON Ruanne Barnabas Timothy W. Menza
COVID-19 IMPACT ON INDEX TESTING SERVICES IN 5 HIGH HIV PREVALENCE INDIAN DISTRICTS
Ajay K. Enugu
O-9 PREVENTION 2021
Oral Abstract Moderators: Raphael J. Landovitz and Landon Myer
IMPACT OF VAGINAL STIs ON bNAb PROTECTION IN MACAQUES
David A. Garber
PHASE 1 PK, SAFETY, AND ACCEPTABILITY STUDY OF 3-MONTH DAPIVIRINE VAGINAL RINGS
Albert Liu
INCIDENCE OF HIV INFECTION WITH DAILY OR ON-DEMAND ORAL PrEP WITH TDF/FTC IN FRANCE
Jean-Michel Molina
IMPACT OF COMMON SIDE EFFECTS ON PrEP PERSISTENCE DURING PREGNANCY IN SOUTH AFRICA Dvora L. Joseph Davey COST-EFFECTIVENESS OF LONG-ACTING PrEP AMONG MSM/TGW IN THE US Anne M. Neilan SOCIAL NETWORKS PREDICT PrEP UPTAKE IN SEARCH STUDY IN RURAL KENYA AND UGANDA Catherine A. Koss HSV-2 ACQUISITION IN A RANDOMIZED TRIAL OF CONTRACEPTIVE METHODS AMONG AFRICAN WOMEN Nelly R. Mugo LABORATORY ANALYSIS OF HIV INFECTIONS IN HPTN 083: INJECTABLE CAB FOR PrEP Raphael J. Landovitz
LIVE PROGRAM Last Updated on March 4, 2021 LIVE PROGRAM LIVE PROGRAM
LIVE PROGRAM
2:30 PM 1:30 PM TIME END EST EST
I I I (1:30 CONCURRENT INTERACTIVE SESSIONS MONDAY, MARCH 8,2021
- - -
3 CONTACT TRACING IN CONTROLLING EPIDEMICS: IS THE WORTH JUICE THE 2 CASE 1 SARS
SQUEEZE? THERAPY CONTACT TRACING GOESVIRAL:VALUE ETHICSAND OF DIGITAL CONTACT TRACING Matthew Golden CONTACT TRACING FOR HIV AND SEXUALLY INFECTIONS TRANSMITTED Chi THE ROLE OFCONTACT TRACING IN EPIDEMIC CONTROL: FACILITATORS AND BARRIERS Moderator: Panelists: Moderator: Penny Moore TION ANTIBODY IMMUNITY TO SARS Paul Bieniasz SELECTION OFNEUTRALIZATION RESISTANT SARS Jeremy Luban STRUCTURE AND FUNCTION OFSARS Morgane Rolland SARS Bette Korber HIV Moderators: Jeffrey Khan
– - - Chi Udeagu
1 Env AND SARS 2:30) -
- - CoV CoV BASED DISCUSSION ONWEIGHT GAININHIV ANDANTIRETROVIRAL
-
Grace McComsey, Sadaf Farooqi, Jane O Jane Farooqi, Grace McComsey, Sadaf
2 EVOLUTION AT THE POPULATION LEVEL - 2 EVOLUTION IN POPULATIONS AND INDIVIDUALS Peter W.Peter Hunt Wafaa El Wafaa
Katharine J. Bar and John Coffin John and Bar J. Katharine
- CoV - Sadr - 2 SPIKE EVOLUTION: SIMILARITIES ANDDIFFERENCES
- CoV -
2 501Y.V2 THROUGH VACCINATION AND INFEC- - CoV - 2 SPIKEPROTEIN VARIANTS
- CoV ’
Halloran, and Cissy Kotyo - 2 MUTANTS
I I I (1:30 CONCURRENT INTERACTIVE SESSIONS TUESDAY, MARCH 9,2020
- - -
6 PrEP SCALE 5 FROM DAILY PILLS TO MONTHLY SHOTS FOR HIV PREVENTION AND TREATMENT: CAN EFFICACY BE 4 HIV TRANSLATED INTO EFFECTIVENESS? INFECTION Mark Dybul CHALLENGES TO PrEP SCALE Elizabeth Irungu PrEP IMPLEMENTATION IN SUB Sheena McCormack THE STAGE:SETTING UNAIDS 2030 GOALS AND CURRENT STATE OFTHE EPIDEMIC Nittaya Phanuphak, Charles Flexner, and Hyman Scott Panelists: Moderators: Ignacio Sanz PATHOLOGICAL B CELL ACTIVATION DURING SARS Robert Seder PROGRAMMING DURABLE IMMUNITY Katie Doores LONGITUDINAL ANTIBODY RESPONSES TO SARS Julie McElrath T CELLIMMUNITY IN SARS Andrés Finzi HUMORAL RESPONSES AGAINST THE SARS Moderators: – -
2:30) 1 AND SARS
Francois Venter,Francois
-
UP TO MEET UNAIDS 2030 GOAL: IT JUST ISN'T POSSIBLE
Carlos del Rio and Diane Havlir Diane and Rio del Carlos Silvestri Guido and Alter Galit
- CoV
- 2: DURABILITY OF HOST IMMUNE RESPONSES FROM VACCINATION OR
-
COV - UP - -
SAHARAN AFRICA 2 NATURAL INFECTION AND FOLLOWING VACCINATION
- CoV
- - 2 SPIKE CoV -
CoV - 2 AND EMERGING VARIANTS
- 2 INFECTION
— OR IS IT?
I I I (1:30 CONCURRENT INTERACTIVE SESSIONS WEDNESDAY, MARCH 10, 2020
- - -
9 COVID 8 COVID 7 SARS Robert E. Fullilove David R.Wilson Mary T. Bassett Moderators: Panelists: Case Presenters and Discussion Moderators: Marcus Buggert Julie Overbaugh Gestur Vidarsson Catherine Blish Benjamin tenOever Nicolas Chomont Moderators: INCARCERATED POPULATIONS AND COVID DISPARITIES IN COVID DISPARITIES IN COVID CASE 2: LONG CASE 1: TREATMENT APPROACHES FOR A PATIENT WITH COVID THE SPECTRUM TCELL OF RESPONSES TO SARS HUMORAL IMMUNE RESPONSES TO SARS AFUCOSYLATED IgG RESPONSES AND SEVERITY IN COVID TOWARDS SWEET THERAP SARS –
2:30) - CoV - CoV - - 19 DISPARITIES: HOW CAN THEY HELP MOVE THE NEEDLE FORWARD? 19 CLINICAL CONTROVERSIES -
Karine Lacombe, Zarir Udwadia, and Claudia Cortes Claudia and Udwadia, Zarir Lacombe, Karine 2 DEBRIS AND ITSCONTRIBUTION TO COVID - 2 AND THE HOST IMMUNE RESPONSE: GOOD VS BAD IMMUNITY Adaora Adimora and Monica Gandhi Monica and Adimora Adaora and Koup A. Richard - TERM OUTCOMES WITH A PATIENT WHORECOVERS FROM COVID
- - 19 IN NATIVE AMERICAN COMMUNITIES 19 AMONG RACIAL AND ETHNIC MINORITIES IN THE US IES FOR SOUR IMMUNOPATHOLOGIES IN COVID
- - COV 19
Roy M. Gulick and Paul E. Sax E. Paul and Gulick M. Roy - - 2 (VIRSCAN) CoV
- 2
- 19 - 19
- 19 INFECTION Last Updatedon March 4,2021
- 19
- 19 INFECTION
ON-DEMAND PROGRAM TIME MONDAY, MARCH 8, 2021 TUESDAY, MARCH 9, 2020 WEDNESDAY, MARCH 10, 2020
SYMPOSIA ARE ON - DEMAND SYMPOSIA (RELEASED EACH DAY AT 12:01 AM) ON-DEMAND SYMPOSIA (RELEASED EACH DAY AT 12:01 AM) ON-DEMAND SYMPOSIA (RELEASED EACH DAY AT 12:01 AM) RELEASED EACH S-1 NAVIGATING TO THE NUCLEUS S-5 IMMUNE-MEDIATING KILLING OF HIV RESERVOIRS: OPPORTUNITIES AND OBSTACLES S-9 NEW FINDINGS AND UNSETTLED CONTROVERSIES IN CENTRAL NERVOUS SYSTEM INFECTION AND DISEASE DAY AT 12:01 Conveners: John M. Coffin and Wesley I. Sundquist Conveners: Nicolas Chomont and Katharine J. Bar Conveners: Dennis L. Kolson and Serena S. Spudich AM EST LIVE-CELL IMAGING: CAPSID TRAFFICKING TO THE NUCLEUS HOW TO GENERATE GOOD KILLERS BY INITIATING ART (NOT TOO) EARLY? NOVEL FINDINGS OF NEURONAL MODULATION OF HIV EXPRESSION IN MICROGLIA Barbara Müller Mark Dybul Jonathan Karn LIVE-CELL IMAGING OF HIV-1 NUCLEAR IMPORT, UNCOATING, AND PROVIRUSES BREAKING THE B-CELL FOLLICLE BARRIER TO ELIMINATE VIRAL RESERVOIRS ROLE OF CNS CD4 T CELLS AND MACROPHAGES IN SIV NEUROPATHOGENESIS AND RESERVOIRS Vanay K. Pathak Afam Okoye Vanessa M. Hirsch VISUALIZATION OF HIV-1 CAPSID-DEPENDENT REPLICATION IN VITRO INTRINSIC RESISTANCE OF RESERVOIR CELLS TO IMMUNE KILLING MYELOID CNS HIV RESERVOIRS...THE DEBATE CONTINUES
Barbie Ganser-Pornillos R. Brad Jones Lishomwa Ndhlovu DEMAND DEMAND PROGRAM - LENACAPAVIR (GS-6207): FIRST CLINICALLY ACTIVE LONG-ACTING INHIBITOR OF HIV CAPSID TYPE I INTERFERON RESISTANCE OF REBOUND HIV-1 LESSONS FROM CNS HIV ESCAPE AND ATI FOR UNDERSTANDING HIV PERSISTENCE IN THE CNS Tomas Cihlar Beatrice H. Hahn Sarah B. Joseph ON S-2 INNATE IMMUNE DEFENSES AGAINST HIV-1 AND SARS-CoV-2 S-6 NOVEL ANTIVIRAL STRATEGIES AND HOW TO DEPLOY THEM S-10 ADOLESCENTS, YOUTH, AND PrEP Conveners: Galit Alter and Frank Kirchhoff Conveners: Joseph J. Eron and Huldrych F. Günthard Conveners: Annette H. Sohn and Connie L. Celum FROM GENOME TO FUNCTION: PHENOTYPIC CHARACTERISATION OF PANDEMIC SARS-CoV-2 VARIANTS TRIPLE DRUG ART, DUAL ART, OR JUST ART? PrEP DURING PREGNANCY AND BREASTFEEDING Volker Thiel Jose R. Arribas John Kinuthia IMMUNE EVASION STRATEGIES BY SARS-CoV-2: Nsp1 AND BEYOND NOVEL ANTIRETROVIRAL THERAPIES IN CLINICAL DEVELOPMENT IMPROVING ADOLESCENT PrEP USE: UNDERSTANDING DEVELOPMENTAL PROCESSES AND CONTEXT Konstantin Sparrer Alexandra L. Calmy Claude A. Mellins SHARED VULNERABILITIES AND DIFFERENT COUNTERMEASURES OF HIV AND SARS-CoV-2 ARVs AND ART FOR NEWBORNS AND INFANTS: A LAST FRONTIER PrEP ADHERENCE INTERVENTIONS FOR ADOLESCENTS AND YOUNG ADULTS Eric O. Freed Moherndran Archary Sybil Hosek IMMUNE RESPONSES TO SARS-CoV-2 GOT ANYTHING FOR THIS COUGH? NEW ANTIVIRALS FOR TREATMENT OF SARS-CoV-2 IMPROVING HOW WE MARKET PrEP TO YOUTH Akiko Iwasaki Davey M. Smith Elzette Rousseau S-3 TUBERCULOSIS: NEW APPROACHES TO PREVENTION AND TREATMENT AND ISSUES FOR PREGNANT WOMEN AND S - 7 COVID -19: FAR MORE THAN JUST THE LUNGS S-11 FOCUS ON THE LIVER: NEW INSIGHTS INTO MANAGEMENT AND CONTROL OF LIVER DISEASE CHILDREN Conveners: Serena S. Spudich and Peter Reiss Conveners: David L. Thomas and Jürgen K. Rockstroh Conveners: Constance A. Benson and Richard E. Chaisson SINGLE VASCULAR CELL HETEROGENEITY IN HEALTH AND DISEASE: A COVID-19 UPDATE HEPATITIS C ELIMINATION: WHAT'S TAKING SO LONG? THE POTENTIAL OF LONG-ACTING INJECTABLE DRUGS FOR PREVENTION AND TREATMENT OF TUBERCULOSIS Peter Carmeliet Annie Luetkemeyer Eric Nuermberger BODY ON FIRE: MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN MECHANISMS AND TREATMENTS OF STEATOSIS IN HIV PREGNANCY, HIV, AND TUBERCULOSIS: CURRENT PRACTICES AND RESEARCH OPPORTUNITIES Elizabeth A. Whittaker Steven Grinspoon Jyoti S. Mathad THINK ABOUT IT: NEUROLOGIC MANIFESTATIONS OF COVID-19 HARNESSING IMMUNITY TO CURE HBV ADVANCES IN PEDIATRIC TUBERCULOSIS PREVENTION AND TREATMENT Benedict D. Michael Ulrike Protzer Nicole Salazar-Austin COVID-19: CONCERNS OF THE HEART NEW PROSPECTS FOR THE TREATMENT OF HBV IMPACT OF COVID-19 PANDEMIC ON HIV AND TUBERCULOSIS: WHO PERSPECTIVE Valentina O. Puntmann Heiner Wedemeyer Souyma Swaminathan S-8 WHAT DOES PrEP DELIVER? S-12 COVID-19 VACCINE: FROM EFFICACY TO EFFECTIVENESS S-4 EFFECT OF HIV ON COVID, EFFECT OF COVID ON HIV Conveners: Connie L. Celum and Monica Gandhi Conveners: Susan P. Buchbinder and Carlos del Rio Conveners: François Dabis and Wafaa M. El-Sadr YOUNG WOMEN: ADHERENCE, EFFECT, AND RETENTION LESSONS LEARNED AND CHALLENGES IN COVID-19 VACCINE TRIALS DOES HIV IMPACT COVID-19 SUSCEPTIBILITY OR SEVERITY? Thesla Palanee-Phillips Kathleen Neuzil Julia Del Amo CHALLENGES AND OPPORTUNITIES IN IMPLEMENTING PrEP IN KEY POPULATIONS EQUITABLE ROLL-OUT OF COVID-19 VACCINES IN THE UNITED STATES THE IMPACT OF COVID-19 ON THE HIV PANDEMIC WORLDWIDE Gregorio A. Millett Michelle A. Williams Andrew D. Kambugu MODELS OF DELIVERING PrEP IN EAST AFRICA: INNOVATIONS AND LESSONS LEARNED VACCINE ACCEPTANCE THE IMPACT OF COVID-19 BEYOND HIV Moses R. Kamya Saad Omer Helen Bygrave INCORPORATING INJECTABLE PrEP AND NEWER FORMULATIONS INTO LMIC GLOBAL DISTRIBUTION OF THE SARS-CoV-2 VACCINE FEAR AND COVID-19: EXPERIENCES ON THE GROUND Yogan Pillay Nicole Lurie Francois Venter
ALL SCIENCE BASIC SCIENCE (A-F) F-1 NEUROIMAGING AND ASSOCIATED BIOMARKERS I-1 NEW DRUGS, OLD DRUGS, AND NEW RESISTANCE MECHANISMS N-1 WHEN VIRUSES COLLIDE: HIV AND SARS-CoV-2 EPIDEMIOLOGY/PUBLIC HEALTH (R-Y) SPOTLIGHTS™ A-1 VIROLOGY OF SARS-CoV-2 F-2 BIOMARKERS AND NEUROCOGNITIVE STATUS I-2 NEW DEVELOPMENTS IN TRANSMITTED AND ACQUIRED DRUG N-2 SARS-CoV-2: MORE THAN A RESPIRATORY VIRUS R-1 COVID-19 EPIDEMIOLOGY ARE RELEASED A-2 VIROLOGY OF HIV F-3 COMORBIDITIES AND NEUROCOGNITIVE OUTCOMES RESISTANCE O-1 TUBERCULOSIS SCREENING AND DETECTION R-2 HIV EPIDEMIOLOGY ON MARCH 6, B-1 ANIMAL MODELS FOR HIV INFECTION F-4 TREATMENT EFFECTS ON NEUROLOGIC OUTCOMES I-3 NEW RESISTANCE TECHNOLOGIES: ADVANTAGES AND LIMITATIONS O-2 TUBERCULOSIS PREVENTION AND TREATMENT R-3 GEOGRAPHIC AND PHYLOGENETIC TRANSMISSION DYNAMICS 2021, AND ARE B - 2 HOST RESPONSE TO SARS-CoV-2 F-5 CNS RESERVOIRS, ESCAPE, AND CONSEQUENCES J-1 HCV: THERAPEUTICS AND PROGRESS TOWARD ELIMINATION O-3 CRYPTOCOCCAL MENINGITIS DETECTION AND OUTCOMES R-4 DISPARITIES AND STRUCTURAL FACTORS AFFECTING HIV CARE J-2 HEPATITIS B: NO LONGER PLAN B OUTCOMES AVAILABLE B-3 OUTCOMES OF SARS-CoV-2 INFECTION F-6 CNS AND PERIPHERAL NERVOUS SYSTEM: MODELS AND MARKERS OF P-1 MATERNAL VIRAL LOAD AND ART ADHERENCE: INSIGHTS AND B-4 HIV AND THE GUT MICROBIOME PATHOGENESIS J-3 MECHANISMS OF HEPATIC INJURY INTERVENTIONS R-5 STIGMA, MENTAL HEALTH, AND SUBSTANCE USE: IMPACT ON THROUGHOUT B-5 NATURAL CONTROL OF HIV INFECTION J-4 HEPATITIS A AND D P-2 CHRONIC COMORBIDITIES IN PREGNANT WOMEN WITH HIV OUTCOMES THE B-6 HOST EFFECTS ON HIV INFECTION CLINICAL (G-Q) J-5 HEPATITIS AND LIVER TRANSPLANTATION P-3 UNDERSTANDING AND IMPROVING PREGNANCY OUTCOMES R-6 MODELING HIV OUTCOMES CONFERENCE B-7 NON T-CELL EFFECTS OF HIV INFECTION G-1 ADVANCES IN ADHERENCE TESTING K1,C1 CANCER: ANAL CANCER AND HPV P-4 EVOLVING INSIGHTS INTO PMTCT SERVICES T-1 RAPID HIV TESTING AND SELF TESTING G-2 EFFECTS OF DRUG DISPOSITION IN THE CSF, LYMPH NODES, LUNG, AND K-2 CANCER: KAPOSI SARCOMA & KAPOSI SARCOMA–ASSOCIATED Q - 1 HEALTH OUTCOMES OF HIV-EXPOSED UNINFECTED CHILDREN AND B-8 HIV AND T CELLS T-2 RECENCY ASSAYS AND INCIDENCE ESTIMATION B-9 HIV-CELL INTERACTION IN VIVO GENITAL TRACT HERPESVIRUS, CERVICAL, LUNG, BREAST, LYMPHOMA, AND HEAD & YOUTH T-3 ROUTINE HIV TESTING D-1 EVOLUTION OF ANTIBODY RESPONSES TO SARS-CoV-2 INFECTION G-3 DRUG-DRUG INTERACTIONS: FROM PREDICTIONS TO MANAGEMENT NECK Q-2 CHARACTERIZING THE VIRAL RESERVOIR AND IMMUNE RESPONSE IN D-2 CELLULAR IMMUNE RESPONSES TO SARS-CoV-2 G-4 NEW APPROACHES TO OPTIMIZE DRUG DOSING: LONG ACTING AND K-3 CANCER: RISK, EPIDEMIOLOGY, AND CARE PEDIATRIC HIV INFECTION T-4 SARS-CoV-2 TESTING AND EFFECT OF COVID-19 ON HIV SCREENING D-3 NOVEL VACCINE CONCEPTS BEYOND L-1 BIOMARKERS OF INFLAMMATION, ART, AND ATHEROSCLEROSIS OR Q - 3 ARVs AND bNAbs FOR CHILDREN AND ADOLESCENTS V-1 LESSONS AND CHALLENGES IN ORAL PrEP IMPLEMENTATION D-4 NEUTRALIZING ANTIBODIES DURING INFECTION H-1 NOVEL TREATMENTS FOR SARS-CoV-2: STARTING AT THE BENCH CARDIOVASCULAR DISEASE Q-4 COMPLICATIONS AND MORTALITY IN CHILDREN AND YOUTH V-2 PrEP ADHERENCE AND CONTROL OF STIs H-2 SARS-CoV-2 TREATMENT: CLINICAL INTERVENTIONS L-2 GLOBAL STUDIES OF CARDIOVASCULAR DISEASE IN HIV Q-5 COVID-19 IN CHILDREN D-5 THE IMPORTANCE OF TISSUE RESIDENCY V-3 NEW PrEP AGENTS AND FORMULATIONS D-6 CHECKING OUT CHECKPOINTS H-3 ANTIRETROVIRAL THERAPY IN THE DEVELOPING WORLD L-3 NOVEL INSIGHTS IN HIV AND CARDIOVASCULAR DISEASE V-4 HIV PREVENTION: CIRCUMCISION AND IDUs E-1 DYNAMICS OF THE HIV RESERVOIR H-4 LONG-ACTING THERAPY: THE TIME HAS COME M-1 WEIGHT GAIN DURING ART X-1 REPRODUCTIVE HEALTH AMONG ADOLESCENTS AT RISK OF HIV E-2 MECHANISMS OF HIV LATENCY H-5 ANTIRETROVIRAL THERAPY: INSIGHTS FROM OBSERVATIONAL STUDIES M-2 TYPE 2 DIABETES DURING ART E-3 INTERVENTIONS TO TARGET THE VIRAL RESERVOIR AND DELAY VIRAL H-6 CLINICAL TRIALS OF ANTIRETROVIRAL THERAPY: TREATMENT NAIVE M-3 EPIDEMIOLOGY OF COMORBIDITIES X-2 EPIDEMIOLOGY OF SYPHILIS AND HIV COINFECTION: THE MORE THINGS CHANGE… REBOUND AND SWITCH M-4 INFLAMMATION AND COMORBIDITIES DURING ART E-4 HIV RESERVOIRS IN CELLS AND TISSUES M-5 FRAILTY AND FUNCTIONAL STATUS X-3 ISSUES IN HIV AND WOMEN'S REPRODUCTIVE HEALTH E-5 CONTROLLERS AND POSTTREATMENT CONTROLLERS M-6 RENAL AND BONE DISEASES Y-1 EFFECT OF COVID-19 ON HIV SERVICES E-6 ASSAYS TO MEASURE AND CHARACTERIZE HIV PERSISTENCE Y-2 THE HIV CARE CASCADE E-6 ASSAYS TO MEASURE AND CHARACTERIZE HIV PERSISTENCE Y-3 DIFFERENTIATED SERVICE DELIVERY Y-4 PREEXPOSURE PROPHYLAXIS Y-5 KEY POPULATIONS
ON-DEMAND PROGRAM Last Updated on March 4, 2021